|
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (May 2013) |
Congenital hypothyroidism |
6 week old female with symptoms of jaundice due to hypothyrodism. This patient was treated with supplemental thyroid hormonal therapy, and appeared to be a normal healthy child at 1 year of age.
|
Classification and external resources |
ICD-10 |
E00, E03.0, E03.1 |
ICD-9 |
243 |
DiseasesDB |
6612 |
MedlinePlus |
001193 |
MeSH |
D003409 |
Congenital hypothyroidism (Styria), copper engraving, 1815
Congenital hypothyroidism (CH) is a condition of thyroid hormone deficiency present at birth. Approximately 1 in 4000 newborn infants has a severe deficiency of thyroid function, while even more have mild or partial degrees. If untreated for several months after birth, severe congenital hypothyroidism can lead to growth failure and permanent intellectual disability. Treatment consists of a daily dose of thyroid hormone (thyroxine) by mouth. Because the treatment is simple, effective, and inexpensive, nearly all of the developed world practices newborn screening to detect and treat congenital hypothyroidism in the first weeks of life.
Contents
- 1 Signs and symptoms
- 2 Cause
- 3 Diagnosis
- 4 Treatment
- 5 Prognosis
- 6 Epidemiology
- 7 References
Signs and symptoms
Infants born with congenital hypothyroidism may show no effects, or may display mild effects that often go unrecognized as a problem: excessive sleeping, reduced interest in nursing, poor muscle tone, low or hoarse cry, infrequent bowel movements, exaggerated jaundice, and low body temperature. If fetal deficiency was severe because of complete absence (athyreosis) of the gland, physical features may include a larger anterior fontanel, persistence of a posterior fontanel, an umbilical hernia, and a large tongue (macroglossia).
In the era before newborn screening, less than half of cases of severe hypothyroidism were recognized in the first month of life. As the months proceeded, these infants would grow poorly and be delayed in their development. By several years of age, they would display the recognizable facial and body features of cretinism. Persistence of severe, untreated hypothyroidism resulted in severe mental impairment, with an IQ below 80 in the majority. Most of these children eventually ended up in institutional care.
-
3 month old infant with untreated CH; picture demonstrates hypotonic posture, myxedematous facies, macroglossia, and umbilical hernia
-
Close up of face, showing myxedematous facies, macroglossia, and skin mottling
-
Close up showing abdominal distension and umbilical hernia.
Cause
Around the world, the most common cause of congenital hypothyroidism is iodine deficiency, but in most of the developed world and areas of adequate environmental iodine, cases are due to a combination of known and unknown causes. Most commonly there is a defect of development of the thyroid gland itself, resulting in an absent (athyreosis) or underdeveloped (hypoplastic) gland. A hypoplastic gland may develop higher in the neck or even in the back of the tongue. A gland in the wrong place is referred to as ectopic, and an ectopic gland at the base or back of the tongue is a lingual thyroid. Some of these cases of developmentally abnormal glands result from genetic defects, and some are "sporadic," with no identifiable cause. One Japanese study found a statistical correlation between certain organochlorine insecticides and dioxin-like chemicals in the milk of mothers who had given birth to infants with congenital hypothyroidism.[1]
In some instances, hypothyroidism detected by screening may be transient. One common cause of this is the presence of maternal antibodies that temporarily impair thyroid function for several weeks.[2]
Cretinism is an old term for the state of mental and physical retardation resulting from untreated congenital hypothyroidism, usually due to iodine deficiency from birth because of low iodine levels in the soil and local food sources. The term, like so many other 19th century medical terms, acquired pejorative connotations as it became used in lay speech. It is now rarely used by physicians.
Genetic
Congenital hypothyroidism can also occur due to genetic defects of thyroxine or triiodothyronine synthesis within a structurally normal gland. Among specific defects are thyrotropin (TSH) resistance, iodine trapping defect, organification defect, thyroglobulin, and iodotyrosine deiodinase deficiency. In a small proportion of cases of congenital hypothyroidism, the defect is due to a deficiency of thyroid stimulating hormone, either isolated or as part of congenital hypopituitarism.
Genetic types of nongoitrous congenital hypothyroidism include:
OMIM |
Name |
Gene |
275200 |
congenital hypothyroidism, nongoitrous 1 CHNG1 |
TSHR |
218700 |
CHNG2 |
PAX8 |
609893 |
CHNG3 |
? at 15q25.3-q26.1 |
275100 |
CHNG4 |
TSHB |
225250 |
CHNG5 |
NKX2-5 |
Nongoitrous congenital hypothyroidism has been described as the "most prevalent inborn endocrine disorder".[3]
Diagnosis
In the developed world, nearly all cases of congenital hypothyroidism are detected by the newborn screening program. These are based on measurement of TSH or thyroxine (T4) on the second or third day of life( Heel prick).
If the TSH is high, or the T4 low, the infant's doctor and parents are called and a referral to a pediatric endocrinologist is recommended to confirm the diagnosis and initiate treatment. Often a technetium (Tc-99m pertechnetate) thyroid scan is performed to detect a structurally abnormal gland. A radioactive iodine (RAIU) exam will help differentiate congenital absence or a defect in organification (a process necessary to make thyroid hormone).
Treatment
The goal of newborn screening programs is to detect and start treatment within the first 1–2 weeks of life. Treatment consists of a daily dose of thyroxine, available as a small tablet. The generic name is levothyroxine, and several brands are available. Commonly used brands in North America are Synthroid, Levoxyl, Unithroid, and Levothroid. The tablet is crushed and given to the infant with a small amount of water or milk. The most commonly recommended dose range is 10-15 μg/kg daily, typically 37.5 or 44 μg.[4] Within a few weeks, the T4 and TSH levels are rechecked to confirm that they are being normalized by treatment. As the child grows up, these levels are checked regularly to maintain the right dose. The dose increases as the child grows.
Prognosis
Most children born with congenital hypothyroidism and correctly treated with thyroxine grow and develop normally in all respects. Even most of those with athyreosis and undetectable T4 levels at birth develop with normal intelligence, although as a population academic performance tends to be below that of siblings and mild learning problems occur in some.[5]
Congenital hypothyroidism is the most common preventable cause of intellectual disability. Few treatments in the practice of medicine provide as large a benefit for as small an effort.
The developmental quotient (DQ, as per Gesell Developmental Schedules) of children with hypothyroidism at age 24 months is summarised below:
. |
Adaptive behavior |
Fine motor |
Gross motor |
Language |
Personal-social behavior |
Severe CH |
92 |
89 |
90 |
89 |
90 |
Moderate CH |
97 |
97 |
98 |
96 |
96 |
Mild CH |
100 |
99 |
100 |
99 |
100 |
[6]
Epidemiology
Neonatal thyroid screening programs from all over the world have revealed that congenital hypothyroidism (CH) occurs with an incidence of 1:3000 to 1:4000.[7][8][9][10] The differences in CH-incidence are more likely due to iodine deficiency thyroid disorders or to the type of screening method than to ethnic affiliation.[7] CH is caused by an absent or defective thyroid gland classified into agenesis (22-42%), ectopy (35-42%) and gland in place defects (24-36%).[7][11] It is also found to be of increased association with female gender and gestational age >40 weeks.[11]
References
- ^ Nagayama J, Kohno H, Kunisue T, et al. (2007). "Concentrations of organochlorine pollutants in mothers who gave birth to neonates with congenital hypothyroidism". Chemosphere 68 (5): 972–6. doi:10.1016/j.chemosphere.2007.01.010. PMID 17307219.
- ^ "Congenital hypothyroidism". Orphanet. August 2010. Retrieved 22 May 2012.
- ^ Grasberger H, Vaxillaire M, Pannain S, et al. (December 2005). "Identification of a locus for nongoitrous congenital hypothyroidism on chromosome 15q25.3-26.1". Hum. Genet. 118 (3–4): 348–55. doi:10.1007/s00439-005-0036-6. PMID 16189712.
- ^ LaFranchi SH, Austin J (2007). "How should we be treating children with congenital hypothyroidism?". J. Pediatr. Endocrinol. Metab. 20 (5): 559–78. doi:10.1515/JPEM.2007.20.5.559. PMID 17642417.
- ^ Moltz KC, Postellon DC (1994). "Congenital hypothyroidism and mental development". Compr Ther 20 (6): 342–6. PMID 8062543.
- ^ Huo K, Zhang Z, Zhao D, Li H, Wang J, Wang, X, Feng H, Wang X, Zhu C (2011). "Risk factors for neurodevelopmental deficits in congenital hypothyroidism after early substitution treatment". Endocrine 58 (5): 355–61. doi:10.1507/endocrj.k10e-384.
- ^ a b c Klett, M (1997). "Epidemiology of congenital hypothyroidism.". Experimental and Clinical Endocrinology & Diabetes. 105 Suppl 4: 19–23. doi:10.1055/s-0029-1211926. PMID 9439909.
- ^ Harris, KB; Pass, KA (July 2007). "Increase in congenital hypothyroidism in New York State and in the United States.". Molecular genetics and metabolism 91 (3): 268–77. doi:10.1016/j.ymgme.2007.03.012. PMID 17512233.
- ^ Deladoey, J.; Belanger, N.; Van Vliet, G. (1 August 2007). "Random Variability in Congenital Hypothyroidism from Thyroid Dysgenesis over 16 Years in Quebec". Journal of Clinical Endocrinology & Metabolism 92 (8): 3158–3161. doi:10.1210/jc.2007-0527. PMID 17504897.
- ^ Olney, RS; Grosse, SD; Vogt RF, Jr (May 2010). "Prevalence of congenital hypothyroidism--current trends and future directions: workshop summary.". Pediatrics. 125 Suppl 2: S31–6. doi:10.1542/peds.2009-1975C. PMID 20435715.
- ^ a b Medda, E; Olivieri, A; Stazi, MA; Grandolfo, ME; Fazzini, C; Baserga, M; Burroni, M; Cacciari, E; Calaciura, F; Cassio, A; Chiovato, L; Costa, P; Leonardi, D; Martucci, M; Moschini, L; Pagliardini, S; Parlato, G; Pignero, A; Pinchera, A; Sala, D; Sava, L; Stoppioni, V; Tancredi, F; Valentini, F; Vigneri, R; Sorcini, M (December 2005). "Risk factors for congenital hypothyroidism: results of a population case-control study (1997-2003).". European journal of endocrinology / European Federation of Endocrine Societies 153 (6): 765–73. doi:10.1530/eje.1.02048. PMID 16322381.
Congenital endocrine disease (Q89.1–Q89.2, 759.1–759.2)
|
|
Pancreas |
|
|
Hypothalamic/
pituitary axes
+parathyroid |
Pituitary
|
- Congenital hypopituitarism
|
|
Thyroid
|
- Persistent thyroglossal duct
- Thyroglossal cyst
- Congenital hypothyroidism: Thyroid dysgenesis
- Thyroid dyshormonogenesis
|
|
Parathyroid
|
- Congenital absence of parathyroid
|
|
Adrenal
|
|
|
Gonads
|
- see congenital reproductive
|
|
|
|
|
Description |
- Glands
- Hormones
- Physiology
- Development
|
|
Disease |
- Diabetes
- Congenital
- Neoplasms and cancer
- Other
- Symptoms and signs
|
|
Treatment |
- Procedures
- Drugs
- calcium balance
- corticosteroids
- oral hypoglycemics
- pituitary and hypothalamic
- thyroid
|
|
|
Cell surface receptor deficiencies
|
|
G protein-coupled receptor
(including hormone) |
Class A |
- TSHR (Congenital hypothyroidism 1)
- LHCGR (Male-limited precocious puberty)
- FSHR (XX gonadal dysgenesis)
- EDNRB (ABCD syndrome, Waardenburg syndrome 4a, Hirschsprung's disease 2)
- AVPR2 (Nephrogenic diabetes insipidus 1)
- PTGER2 (Aspirin-induced asthma)
|
|
Class B |
- PTH1R (Jansen's metaphyseal chondrodysplasia)
|
|
Class C |
- CASR (Familial hypocalciuric hypercalcemia)
|
|
Class F |
- FZD4 (Familial exudative vitreoretinopathy 1)
|
|
|
Enzyme-linked receptor
(including
growth factor) |
RTK |
- ROR2 (Robinow syndrome)
- FGFR1 (Pfeiffer syndrome, KAL2 Kallmann syndrome)
- FGFR2 (Apert syndrome, Antley–Bixler syndrome, Pfeiffer syndrome, Crouzon syndrome, Jackson–Weiss syndrome)
- FGFR3 (Achondroplasia, Hypochondroplasia, Thanatophoric dysplasia, Muenke syndrome)
- INSR (Donohue syndrome
- Rabson–Mendenhall syndrome)
- NTRK1 (Congenital insensitivity to pain with anhidrosis)
- KIT (KIT Piebaldism, Gastrointestinal stromal tumor)
|
|
STPK |
- AMHR2 (Persistent Müllerian duct syndrome II)
- TGF beta receptors: Endoglin/Alk-1/SMAD4 (Hereditary hemorrhagic telangiectasia)
- TGFBR1/TGFBR2 (Loeys-Dietz syndrome)
|
|
GC |
- GUCY2D (Leber's congenital amaurosis 1)
|
|
|
JAK-STAT |
- Type I cytokine receptor: GH (Laron syndrome)
- CSF2RA (Surfactant metabolism dysfunction 4)
- MPL (Congenital amegakaryocytic thrombocytopenia)
|
|
TNF receptor |
- TNFRSF1A (TNF receptor associated periodic syndrome)
- TNFRSF13B (Selective immunoglobulin A deficiency 2)
- TNFRSF5 (Hyper-IgM syndrome type 3)
- TNFRSF13C (CVID4)
- TNFRSF13B (CVID2)
- TNFRSF6 (Autoimmune lymphoproliferative syndrome 1A)
|
|
Lipid receptor |
- LRP: LRP2 (Donnai–Barrow syndrome)
- LRP4 (Cenani–Lenz syndactylism)
- LRP5 (Worth syndrome, Familial exudative vitreoretinopathy 4, Osteopetrosis 1)
- LDLR (LDLR Familial hypercholesterolemia)
|
|
Other/ungrouped |
- Immunoglobulin superfamily: AGM3, 6
- Integrin: LAD1
- Glanzmann's thrombasthenia
- Junctional epidermolysis bullosa with pyloric atresia
EDAR (EDAR Hypohidrotic ectodermal dysplasia)
- PTCH1 (Nevoid basal cell carcinoma syndrome)
- BMPR1A (BMPR1A Juvenile polyposis syndrome)
- IL2RG (X-linked severe combined immunodeficiency)
|
|
- See also
- cell surface receptors
Index of disease relating to protein defects
|
|
Disease |
- B structural
- perx
- skel
- cili
- mito
- nucl
- sclr
- DNA/RNA/protein synthesis
- membrane
- transduction
- trfk
|
|
|
Genetic disorder, protein biosynthesis: Transcription factor/coregulator deficiencies
|
|
(1) Basic domains |
1.2 |
- Feingold syndrome
- Saethre–Chotzen syndrome
|
|
1.3 |
|
|
|
(2) Zinc finger
DNA-binding domains |
2.1 |
- (Intracellular receptor): Thyroid hormone resistance
- Androgen insensitivity syndrome
- Kennedy's disease
- PHA1AD pseudohypoaldosteronism
- Estrogen insensitivity syndrome
- X-linked adrenal hypoplasia congenita
- MODY 1
- Familial partial lipodystrophy 3
- SF1 XY gonadal dysgenesis
|
|
2.2 |
- Barakat syndrome
- Tricho–rhino–phalangeal syndrome
|
|
2.3 |
- Greig cephalopolysyndactyly syndrome/Pallister–Hall syndrome
- Denys–Drash syndrome
- Duane-radial ray syndrome
- MODY 7
- MRX 89
- Townes–Brocks syndrome
- Acrocallosal syndrome
- Myotonic dystrophy 2
|
|
2.5 |
- Autoimmune polyendocrine syndrome type 1
|
|
|
(3) Helix-turn-helix domains |
3.1 |
- ARX
- Ohtahara syndrome
- Lissencephaly X2
- MNX1
- HOXD13
- PDX1
- LMX1B
- MSX1
- Tooth and nail syndrome
- OFC5
- PITX2
- POU4F3
- POU3F4
- ZEB1
- Posterior polymorphous corneal dystrophy
- Fuchs' dystrophy 3
- ZEB2
|
|
3.2 |
- PAX2
- PAX3
- PAX4
- PAX6
- Gillespie syndrome
- Coloboma of optic nerve
- PAX8
- Congenital hypothyroidism 2
- PAX9
|
|
3.3 |
- FOXC1
- Axenfeld syndrome 3
- Iridogoniodysgenesis, dominant type
- FOXC2
- Lymphedema–distichiasis syndrome
- FOXE1
- Bamforth–Lazarus syndrome
- FOXE3
- Anterior segment mesenchymal dysgenesis
- FOXF1
- FOXI1
- Enlarged vestibular aqueduct
- FOXL2
- Premature ovarian failure 3
- FOXP3
|
|
3.5 |
- IRF6
- Van der Woude syndrome
- Popliteal pterygium syndrome
|
|
|
(4) β-Scaffold factors
with minor groove contacts |
4.2 |
- Hyperimmunoglobulin E syndrome
|
|
4.3 |
- Holt–Oram syndrome
- Li–Fraumeni syndrome
- Ulnar–mammary syndrome
|
|
4.7 |
- Campomelic dysplasia
- MODY 3
- MODY 5
- SF1
- SRY XY gonadal dysgenesis
- Premature ovarian failure 7
- SOX10
- Waardenburg syndrome 4c
- Yemenite deaf-blind hypopigmentation syndrome
|
|
4.11 |
|
|
|
(0) Other transcription factors |
|
|
Ungrouped |
- TCF4
- ZFP57
- TP63
- Rapp–Hodgkin syndrome/Hay–Wells syndrome/Ectrodactyly–ectodermal dysplasia–cleft syndrome 3/Limb–mammary syndrome/OFC8
|
|
Transcription coregulators |
Coactivator: |
- CREBBP
- Rubinstein–Taybi syndrome
|
|
Corepressor: |
- HR (Atrichia with papular lesions)
|
|
|
See also transcription factors and intracellular receptors
Index of disease relating to protein defects
|
|
Disease |
- B structural
- perx
- skel
- cili
- mito
- nucl
- sclr
- DNA/RNA/protein synthesis
- membrane
- transduction
- trfk
|
|
|
Extracellular ligand disorders
|
|
Cytokine |
- EDA Hypohidrotic ectodermal dysplasia
- Camurati-Engelmann disease
|
|
Ephrin |
- Craniofrontonasal dysplasia
|
|
WNT |
|
|
TGF |
|
|
Fas ligand |
- Autoimmune lymphoproliferative syndrome 1B
|
|
Endothelin |
- EDN3
- Waardenburg syndrome IVb
- Hirschsprung's disease 4
|
|
Other |
- DHH (DHH XY gonadal dysgenesis)
- BMP15 (Premature ovarian failure 4)
- TSHB (Congenital hypothyroidism 4)
|
|
- See also
- intercellular signaling peptides and proteins
Index of disease relating to protein defects
|
|
Disease |
- B structural
- perx
- skel
- cili
- mito
- nucl
- sclr
- DNA/RNA/protein synthesis
- membrane
- transduction
- trfk
|
|
|